Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work

被引:565
作者
Kumar, Rajesh [1 ]
Harilal, Seetha [1 ]
Gupta, Sheeba Varghese [2 ]
Jose, Jobin [3 ]
Parambi, Della Grace Thomas [4 ]
Uddin, Md. Sahab [5 ,6 ]
Shah, Muhammad Ajmal [7 ]
Mathew, Bijo [8 ,9 ]
机构
[1] Kerala Univ Hlth Sci, Dept Pharm, Trichur, Kerala, India
[2] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33612 USA
[3] NITTE Deemed Univ, NGSM Inst Pharmaceut Sci, Dept Pharmaceut, Manglore 575018, India
[4] Jouf Univ, Coll Pharm, Dept Pharmaceut Chem, Sakaka 2014, Al Jouf, Saudi Arabia
[5] Southeast Univ, Dept Pharm, Dhaka, Bangladesh
[6] Pharmakon Neurosci Res Network, Dhaka, Bangladesh
[7] Govt Coll Univ, Fac Pharmaceut Sci, Dept Pharmacogonosy, Faisalabad, Pakistan
[8] Ahalia Sch Pharm, Dept Pharmaceut Chem, Div Drug Design, Palakkad 678557, Kerala, India
[9] Ahalia Sch Pharm, Dept Pharmaceut Chem, Med Chem Res Lab, Palakkad 678557, Kerala, India
关键词
Drug repurposing; Drug repositioning; Clinical trials; Lead molecule; ENDOTHELIAL GROWTH-FACTOR; ONLINE MENDELIAN INHERITANCE; PHARMACOKINETIC PROPERTIES; TARGET INTERACTION; TOPICAL MINOXIDIL; OLD DRUGS; PHASE-II; CANCER; EXPRESSION; DISCOVERY;
D O I
10.1016/j.ejmech.2019.111602
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug discovery and development are long and financially taxing processes. On an average it takes 12-15 years and costs 1.2 billion USD for successful drug discovery and approval for clinical use. Many lead molecules are not developed further and their potential is not tapped to the fullest due to lack of resources or time constraints. In order for a drug to be approved by FDA for clinical use, it must have excellent therapeutic potential in the desired area of target with minimal toxicities as supported by both pre-clinical and clinical studies. The targeted clinical evaluations fail to explore other potential therapeutic applications of the candidate drug. Drug repurposing or repositioning is a fast and relatively cheap alternative to the lengthy and expensive de novo drug discovery and development. Drug repositioning utilizes the already available clinical trials data for toxicity and adverse effects, at the same time explores the drug's therapeutic potential for a different disease. This review addresses recent developments and future scope of drug repositioning strategy. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:17
相关论文
共 229 条
[1]   Drug repurposing for the treatment of glioblastoma multiforme [J].
Abbruzzese, Claudia ;
Matteoni, Silvia ;
Signore, Michele ;
Cardone, Luca ;
Nath, Kavindra ;
Glickson, Jerry D. ;
Paggi, Marco G. .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2017, 36
[2]   Speeding disease gene discovery by sequence based candidate prioritization [J].
Adie, EA ;
Adams, RR ;
Evans, KL ;
Porteous, DJ ;
Pickard, BS .
BMC BIOINFORMATICS, 2005, 6 (1)
[3]  
Agrawal R., 1998, SIGMOD Record, V27, P94, DOI 10.1145/276305.276314
[4]   Identification of Nitazoxanide as a Group I Metabotropic Glutamate Receptor Negative Modulator for the Treatment of Neuropathic Pain: An In Silico Drug Repositioning Study [J].
Ai, Ni ;
Wood, Richard D. ;
Welsh, William J. .
PHARMACEUTICAL RESEARCH, 2015, 32 (08) :2798-2807
[5]   The C-Terminal Domain of the Arabinosyltransferase Mycobacterium tuberculosis EmbC Is a Lectin-Like Carbohydrate Binding Module [J].
Alderwick, Luke J. ;
Lloyd, Georgina S. ;
Ghadbane, Hemza ;
May, John W. ;
Bhatt, Apoorva ;
Eggeling, Lothar ;
Fuetterer, Klaus ;
Besra, Gurdyal S. .
PLOS PATHOGENS, 2011, 7 (02)
[6]   DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information [J].
Amelio, I. ;
Gostev, M. ;
Knight, R. A. ;
Willis, A. E. ;
Melino, G. ;
Antonov, A. V. .
CELL DEATH & DISEASE, 2014, 5 :e1051-e1051
[7]   Drug Repurposing for the Treatment of Acute Myeloid Leukemia [J].
Andresen, Vibeke ;
Gjertsen, Bjorn T. .
FRONTIERS IN MEDICINE, 2017, 4
[8]  
Ankerst M, 1999, SIGMOD RECORD, VOL 28, NO 2 - JUNE 1999, P49
[9]  
[Anonymous], NONPEPTIDE ARGININE
[10]  
[Anonymous], 2013, TRIAL WATCH PHASE 2